PubMed Health⌕ Search

PubMed · 17014119

Water behavior revisited at the air/ionic solution and silica/ionic solution interfaces. Extension to coadsorption of ions and organic molecules.

Abstract

This paper reports on investigations about the adsorption at the air-water surface, and for the sake of comparison at the silica-solution interface, of two 1-2 electrolytes, Pb(NO(3))(2) and PbCl(2), at first alone and then from a mixture with carbofuran or with benzene; all of them were at concentrations below 10(-2) M. The limited domain, where the Debye and Hückel formalism for solutions and the Wagner-Onsager-Samaras (WOS) model for surfaces are correct, is then respected. This study was aimed at trying to identify the part played in the surface by the different particles of the system components and in particular the role of water. When aqueous solutions of nonorganic salts are dilute enough, their surface tensions are known to be salt concentration-independent; however, the zero value of the resulting relative adsorption has never been the subject of analysis about water behavior. By combining experimental relative adsorptions and Gibbs excesses calculated from the WOS theory, we will show that, in well-known solutions such as KCl ones, where the negative excess in salt can be very precisely modeled by the WOS theory, the resulting water excess Gamma(W) is negative. The same result can be obtained by taking into account the Ray-Jones effect. This observation drove us to wonder about the results of a similar analysis done on solutions of unsymmetrical electrolytes and on mixtures of salt and organic molecules. Experiments showed that, for all of the systems, Gamma(W) was negative. For a given salt, Gamma(W) was more negative in the presence of organic molecules, and carbofuran was a more efficient water repellent than benzene; water repulsion was greater with nitrates than with chlorides. From these data, it seems that water was repelled toward the solution bulk, whereas ions probably took place between the bulk and a layer of organic molecules. These observations called for a more detailed modeling.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Abdelhaq Acharid, Mustapha Sadiki, Galal Elmanfe, Nawal Derkaoui, René Olier, Mireille Privat. 2006-10-10. Water behavior revisited at the air/ionic solution and silica/ionic solution interfaces. Extension to coadsorption of ions and organic molecules.. https://doi.org/10.1021/la061160c

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗